News

For organizations looking to increase transparency in the study startup process, the sheer volume of data and the silos in which they exist can be a daunting hurdle. New generation systems enable teams to capture, analyze, share, and visualize study startup data in one system.

ECT is comprised of two primary services, Protocol+ for the registration of trials and Results Services for the publications of trial results.

The European drug research consortium, IMI2, is running a program entitled Big Data for Better Outcomes Programme to promote "the evolution towards value-based and more outcomes-focused" healthcare, by generating methodologies and data that can inform policy debates.

The number of countries used in commercially sponsored Phase III clinical trials has not changed in recent years.

The Ethical eAdjudication® Platform will join ACRES shared global platform of integrated technologies.

The burst of new technology enterprises and innovative service providers that specialize in clinical research is a sign that the clinical research industry is starting to look into new ways to solving problems culminating from an antiquated system.

ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.

The discussions will center on ways clinical research can harness gene therapy and new and emerging diagnostic tools.

Examining why newly registered trials have fallen in Central and Eastern Europe, relative to other regions.

Survey sheds light on the regional-specific risks of managing clinical trial sites in Eastern Europe.

Study uncovers subtle distinctions in attitudes and perceptions among the two groups.

EMA expects a small rise in the pre-authorization activities for human medicines in 2016. Around 546 requests for scientific advice are anticipated, compared to 510 in 2015.

Managed by EMA on behalf of the EU medicines regulatory network, EudraVigilance receives over one million adverse drug reaction reports per year.

Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and RBM capabilities into multiple stages of its drug development process.

Many of the most problematic provisions for health research were eased by amendments that provided exemptions from the overall constraints.

The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase.

The December Forum included discussions of global disclosure performance, and highlighted the importance of measuring disclosure performance.